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Abstract
Engineered proteins are being widely developed and employed in applications
ranging from enzyme catalysts to therapeutic antibodies. Directed evolution, an itera-
tive experimental process composed of mutagenesis and library screening, is a
powerful technique for enhancing existing protein activities and generating entirely
new ones not observed in nature. However, the process of accumulating mutations
for enhanced protein activity requires chemical and structural changes that are often
destabilizing, and low protein stability is a significant barrier to achieving large
enhancements in activity during multiple rounds of directed evolution. Here we high-
light advances in understanding the origins of protein activity/stability trade-offs for
two important classes of proteins (enzymes and antibodies) as well as innovative
experimental and computational methods for overcoming such trade-offs. These
advances hold great potential for improving the generation of highly active and stable
proteins that are needed to address key challenges related to human health, energy
and the environment.
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1 | INTRODUCTION
Proteins encode diverse activities through their complex 3D structures
that are essential for life. These natural activities range from catalysis of
a wide range of chemical reactions (enzymes) to specific and high-affinity
recognition of target molecules (antibodies). Many naturally occurring
protein functions have been harnessed for technological applications,
including specialty chemical production1-4 and disease-modifying thera-
peutics.5-7 However, natural proteins rarely possess the particular bio-
physical and/or functional properties required for a given application,
such as protein activity in extreme conditions (e.g., high temperature or
harsh solvent conditions)8,9 or entirely new protein functions not found
in nature.10,11 Consequently, proteins intended for use in
biotechnological applications generally require moderate to extensive
engineering and optimization to satisfy these unique constraints.12-14
The process of performing directed evolution is relatively simple in
concept, as it “only” requires two key steps. The first step is creating pro-
tein libraries by introducing mutations into the target protein either in a
random or targeted manner. The second step is screening the protein
libraries in a manner that enables identification of rare variants with
improved protein properties such as catalytic activity. In practice, many
studies have shown that the success of directed evolution experiments is
strongly influenced by the quality of both the protein libraries and screen-
ing methods that are employed. One common challenge in such studies is
that “you get what you screen for” and activity screens commonly yield
proteins with increased activity but compromised stability (Figure 1).
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The origin of problematic protein activity/stability trade-offs during
directed evolution is linked to multiple factors. First, proteins tend only
to be marginally stable at their physiological conditions,15 and mutations
in proteins carry significant risk for reducing stability.16-18 Second, muta-
tions that promote gains in protein activity necessarily lead to chemical
and structural changes, and these changes are rarely optimal for the exis-
ting protein scaffold and have an increased likelihood of reducing protein
stability. Indeed, many protein functions gained through directed
evolution—especially those that involve multiple rounds of mutation and
selection—come at the cost of reduced protein stability.18-22 Although
bottlenecks in directed evolution frequently arise as a result of protein
destabilization (Figure 1), new experimental and computational advances
are enabling the navigation of protein fitness landscapes in an effective
and efficient manner. In honor of Francis Arnold's Nobel Prize in Chemis-
try for her pioneering work in the area of directed evolution, we review
a number of key fundamental studies over the last few decades as well
as emerging technologies that are increasing the success of evolving pro-
teins with both high activity and high stability.
2 | DIRECTED EVOLUTION METHODS FOR
SELECTING PROTEINS WITH HIGH ACTIVITY
AND STABILITY
2.1 | Cell survival screens for optimizing enzyme
activity and stability
The power of directed evolution is only truly realized when robust
screens for protein function can be developed that successfully iden-
tify improved protein variants. Clonal screening often represents the
biggest bottleneck in directed evolution studies because many protein
activities are relatively difficult to screen for in a high-throughput
manner. The most attractive types of protein activities that have been
engineered using directed evolution are those that enable survival of
a host (e.g., bacterial or yeast), such as enhanced enzymatic activity
against antibiotics that promotes bacterial survival. In such cases, it is
possible to screen relatively large libraries (106–1010)—which are typi-
cally limited in size by DNA transformation efficiency—for improved
protein function by selecting cells that survive in conditions requiring
higher activity than observed for the wild-type protein without the
need to individually evaluate each mutant.
Indeed, one of the most well-studied enzymes in the field of
directed evolution is β-lactamase, which is an attractive enzyme to evo-
lve because its activity (conferring resistance to penicillins) can be easily
screened for in bacteria by identifying antibiotic-resistant colonies.
Additionally, the structure and function of many β-lactamases have
been studied in detail,23-25 providing a unique opportunity to investi-
gate trade-offs between stability and activity in a well-understood
enzyme family. The overall stability of enzymes (and other proteins)
results from the organization of a large network of favorable intramo-
lecular interactions, including the stable packing of the hydrophobic
core surrounded by solvent-exposed hydrophilic residues and hydrogen
bonding networks between elements of secondary structure. However,
mutations in and near the active site—which are required for binding
ligands and mediating catalysis—have an increased risk of destabilizing
enzymes because of their propensity to disrupt the network of intramo-
lecular interactions that collectively govern protein stability.22,26,27
An elegant dissection of the molecular determinants of enzyme
activity/stability trade-offs has been reported for β-lactamase.27 The
authors sought not to improve β-lactamase activity, but rather to test if
its key active site residues are generally destabilizing and if mutating
these sites to less active residues would be stabilizing. Notably, the
authors found that mutating many active site residues to less active
ones resulted in significant increases in stability. For example, a single
mutation of a key active site residue (Ser64) to a less active one
(Asp64) was sufficient to increase stability by 30%, which is particularly
surprising given that the enzyme has >300 residues. Conversely, the
investigators found that several other solvent-exposed, nonactive-site
mutations had little effect on β-lactamase stability.
Analysis of the structural mechanisms for this and related active-
site mutations that also reduced β-lactamase activity revealed several
common mechanisms.27 First, the nature of the active site for wild-
type β-lactamase (and for enzymes in general) is such that binding to
F IGURE 1 Directed evolution of proteins such as enzymes and
antibodies to achieve increased or new activities often results in
reduced stability, and low protein stability is a common barrier to
protein evolvability. To achieve significant gains in protein activity, it is
typically necessary to also select compensatory (stabilizing) mutations
that enable the accumulation of activity-enhancing, destabilizing
mutations while maintaining protein thermodynamic stability [Color
figure can be viewed at wileyonlinelibrary.com]
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the substrate fulfills otherwise unsatisfied intramolecular interactions.
Thus, mutating active site residues to less active ones that are larger
and/or which contain additional functional groups (e.g., Ser to Asp at
position 64) that are able to mimic substrate binding and satisfy key
intramolecular interactions increases protein stability. Second, stabiliz-
ing mutations in the active site that reduce β-lactamase activity also
frequently reduce steric or electrostatic strain (or both) in the enzyme
3D structure. For example, the authors observed large increases in
stability (and reduced activity) due to reductions in steric strain via
mutation of a key active site residue (Ser64) to a smaller and more
flexible one (Gly64). These and other findings22,28-30 demonstrate that
the structural and chemical requirements for high activity and high
stability of enzymes are not only different, but often at odds with one
another.
A particularly interesting example of enzyme activity/stability
trade-offs has been observed for β-lactamase (TEM-1) mutants identi-
fied in clinical isolates.31 While the wild-type enzyme is effective at
degrading penicillins, it has little activity against other classes of antibi-
otics such as cephalosporins. Notably, mutants of β-lactamase observed
in clinical isolates gain activity against cephalosporins. These mutants
have several intriguing properties. First, the mutations that increase the
size of the active site cavity to accommodate cephalosporins are
destabilizing. Second, many of the mutants that are active against ceph-
alosporins possess an additional compensatory mutation distal from the
active site that compensates for the destabilizing effects of the active-
site mutations. These findings further highlight the inherent trade-offs
between enzyme stability and activity, and demonstrate how compen-
satory mutations are required to maintain thermodynamic stability as
enzyme activity is enhanced via active-site mutations.
It is also notable that the wild-type and mutant β-lactamase vari-
ants in these studies27,31 have modest thermal stabilities (<60C).
While this level of stability is suitable for physiological enzyme func-
tion, it is not ideal for applications that require enzyme function (and
therefore enzyme stability) at higher temperatures. To screen for
enzyme variants with higher stability using cell survival methods, it is
necessary to use cellular hosts that survive at such elevated tempera-
tures. This need has led to the use of thermophiles in directed evolu-
tion studies—most commonly thermophilic bacteria—that thrive at
elevated temperatures.
Two pioneering studies investigated the use of a thermophilic bac-
terium (B. stearothermophilus) to screen for highly stable variants of
kanamycin nucleotidytransferase (KNTase), an enzyme that degrades
the antibiotic kanamycin.32,33 The wild-type enzyme fails to support
growth of the thermophile at temperatures above ~55C in the pres-
ence of kanamycin. Therefore, the investigators introduced mutations
into the enzyme using several different approaches and screened for
rare variants that promoted bacterial growth at elevated temperatures
(61–71C). Encouragingly, using disparate mutagenesis and selection
methods, two entirely different research groups identified the same
mutations (D80Y and T130 L) that significantly stabilized the wild-
type enzyme by >10C. These and other34-37 studies have established
creative and powerful approaches for using thermophiles to identify
highly active, thermostable enzymes.
2.2 | Functional (survival-independent) screens for
optimizing enzyme activity and stability
Despite the power of performing directed evolution using cell survival
screens, this approach is not readily applicable to most enzymes or
other types of proteins because it is challenging in general to link pro-
tein functions to cell survival. Therefore, most directed evolution
studies of enzymes are performed via functional (noncell survival)
screens in which the properties of each protein variant are directly evalu-
ated. In such cases, the screens must be conducted on a clone-by-clone
basis, which significantly decreases throughput. An outcome of these
low-throughput methods is the enzyme library sizes that can be screened
are much smaller than what is possible using cell survival selections. For
example, traditional functional screens for enzyme libraries performed in
microtiter plates typically involve screening ~102–104 mutants38-40 rela-
tive to cell survival methods where library size is typically limited by trans-
formation efficiency (106–1010 variants).
However, there are a number of emerging technologies for improv-
ing the throughput of functional screens for directed evolution of
enzymes and other types of proteins (as summarized in multiple recent
reviews40-42). A critical element of any enzymatic screen is the spatial
isolation (compartmentalization) of each protein variant in the library to
maintain the linkage between enzyme function and DNA sequence as
well as the linkage between enzyme function and its catalytic products.
To accomplish this, several innovative approaches have been reported
that shrink the size of compartments from those common for microtiter
plates (microliters) to extremely small droplets or wells (nanoliters). These
approaches enable the screening of several orders of magnitude more
enzyme variants. These important advances—which are still in their
infancy and are associated with some additional challenges—will likely
continue to mature in the coming years and be invaluable for directed
evolution studies. In this review, we focus on studies that have primarily
used conventional, lower-throughput screening methods for enzyme
engineering.
Perhaps no class of biotechnologically relevant enzymes has
been as extensively studied and engineered in recent years as cyto-
chrome P450s. Thousands of cytochrome P450s, which catalyze
mainly oxygenation reactions for a wide variety of organic substrates,43,44
have been identified from all kingdoms of life and are important for
chemoenzymatic synthesis, bioconversion, and bioremediation.44-46
Cytochrome P450s are hemeproteins that generally function in con-
cert with an NAD(P)H-driven redox partner to facilitate electron
transfer to the heme iron during catalysis and/or use hydrogen
peroxide to directly generate reactive heme iron-oxo species.
Conveniently, some cytochrome P450s are naturally encoded as
self-sufficient catalytic fusion proteins containing a reductase
domain (e.g., cytochrome P450BM3). Others have been engineered
for enhanced activity as peroxygenases,47,48 which eliminates the
need for expensive and complicated cofactor regeneration schemes.
Their promiscuity enables them to accept a broad range of sub-
strates, which has motivated researchers to engineer cytochrome
P450s for oxygenation reactions on novel substrates.48-52
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However, repurposing enzymes such as cytochrome P450s to
accept new substrates and/or catalyze new reactions typically
requires significant mutagenesis in and/or near their active sites. The
trade-offs between P450 activity and stability have been dissected by
Frances Arnold's lab in a particularly clear and detailed manner. An
impressive example is highlighted in Figure 2.19,20,50,53 The Arnold lab
asked whether a particular P450 (P450BM3)—which hydroxylates long-
chain fatty acids (C12–C20)—could conduct the same reaction for an
entirely different substrate (short-chain alkanes, C2–C3). This goal is
important because alkanes are both common and relatively inert,54,55
and converting inert C─H bonds to reactive C─OH bonds enables the
use of such upgraded chemicals as feedstocks in many key industrial
processes and is also important for bioremediation.56,57 However, this
is generally a challenging problem due to the lack of efficient catalysts
for hydroxylating short alkanes (e.g., propane) and in particular for
evolving the P450BM3 enzyme, which completely lacks activity against
short alkanes.
One of the Arnold lab's most influential contributions to the field
of directed evolution is its demonstration that greatly improved or
entirely new functions can be engineered into proteins if only modest
improvements are required in each round of evolution and this pro-
cess of mutagenesis and selection is repeated many times.19,50,58,59
Indeed, they used this progressive evolution approach to eventually
evolve a variant of the P450BM3 enzyme that hydroxylates short-chain
alkanes (P450 propane monooxygenase) in a highly efficient, native-
like manner. To accomplish this, they made a key initial observation
that the wild-type enzyme had weak but detectable activity against
long-chain alkanes (C8 and larger). This observation led them to per-
form selections for mutations in the wild-type enzyme not for activity
against short-chain alkanes (their eventual goal) but rather initially
against long-chain alkanes (C8). Notably, the most active mutant
enzyme identified in the initial screen against long-chain alkanes
acquired low levels of catalytic activity against propane. This variant
was then subjected to further mutagenesis and selection in the next
round of directed evolution against alkanes that were modestly
shorter. This process of mutagenesis and selection was repeated mul-
tiple times to enhance the rate of propane hydroxylation.
However, at one point in this directed evolution process, it was
observed that the mutated P450 enzyme (35E11) could not be further
evolved for additional increases in activity and did not meet the target
F IGURE 2 Directed evolution of enzymes reveals trade-offs between activity and stability. (a) Directed evolution experiments are composed
of several steps, beginning with mutagenesis of a parent gene and then screening for the desired protein function (e.g., catalytic activity against a
desired substrate). Mutants with improved performance are identified and their DNA sequences are used for subsequent rounds of mutagenesis
and protein optimization. (b, c) A cytochrome P450 enzyme was engineered for a novel function, namely hydroxylation of a short-chain alkane
(propane), and its (b) catalytic activity towards propane (total turnover number) and (c) temperature of half-inactivation (T50) are reported. After
three rounds of evolution, an optimization plateau was reached as a result of the low stability of the 35E11 mutant enzyme. This plateau was
overcome by introducing several stabilizing mutations (leading to the stabilized ETS8 variant), which enabled subsequent rounds of directed
evolution to further improve enzyme activity. The data were obtained from previous publications from the Arnold lab,19,20 and the figure was
adapted from a previous one53 [Color figure can be viewed at wileyonlinelibrary.com]
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goal of a highly efficient hydroxylation catalyst against short-chain
alkanes (Figure 2).19,20,50,53 Evaluation of the stability of the evolved
enzymes up to the point of failure revealed that enzyme stability pro-
gressively decreased as hydroxylation activity increased. For example,
the temperature at which the wild-type enzyme was inactivated by
50% (T50) was ~55C, but this was reduced to only 43C for the
evolved enzyme (35E11) after the third round of evolution. This com-
promised stability—due to accumulation of activity-enhancing
mutations—appeared to explain the inability to further evolve P450
hydroxylation activity against short-chain alkanes.
To address the problem of poor stability of the P450 enzyme
mutant (35E11), the Arnold lab performed a round of mutagenesis
and selection aimed at increasing enzyme stability without signifi-
cantly reducing enzyme activity (Figure 2).19,20,53 Notably, they incor-
porated mutations previously shown to stabilize a related P450
enzyme that they found also significantly stabilized the mono-
oxygenase (increase of T50 of >5C), and this resulted in only modest
decreases in enzyme activity. At this point, it was not obvious that the
stabilized enzyme could be further evolved for additional increases in
activity without simply being limited again by poor stability. However,
the Arnold lab used their incremental approach of directed evolution
to eventually achieve a P450 that hydroxylates propane with a cata-
lytic efficiency similar to the efficiencies of natural P450s against their
preferred substrates. Notably, the stability of the highly evolved pro-
pane monooxygenase variant (PMO) was reduced almost to the point
of the variant that could not be further evolved for increased activity
(35E11), suggesting that even greater improvements in enzyme activ-
ity would likely require additional stabilizing mutations.
What do we learn from these exciting studies? First, very large
changes in enzyme function can be achieved gradually by requiring
only modest activity improvements in any single round of directed
evolution. Given that directed evolution studies commonly fail to
meet all of their objectives, it is likely that such failures are due
(at least in part) to using screening methods that require too large of
an activity improvement in any given round of directed evolution. Sec-
ond, these studies suggest that trade-offs between enzyme activity
and stability are the norm, not the exception. The extensive mutagen-
esis of the P450 enzymes required to achieve large improvements in
activity against short-chain alkanes necessarily resulted in reduced
stability, and this trend was observed even after the P450 enzymes
were stabilized at an intermediate step in the evolutionary process
(Figure 2c).19,20,53 These and related findings in the Arnold lab60-64
have greatly advanced the field of directed evolution and provided
valuable approaches for overcoming inherent trade-offs between
enzyme activity and stability.
Another important application of functional (noncell survival)
screens is the evolution of enzymes with high stability at elevated
temperatures that are required for diverse biotechnology applications.
For cases in which extremely high stability is required, it can be chal-
lenging to identify stabilizing mutations for enzymes that are already
moderately to highly stable. One powerful approach to address this
challenge is to first introduce destabilizing mutations into enzymes at
the beginning of the directed evolution process to reduce stability in
order to simplify the identification of stabilizing mutations at other
sites. It was hypothesized that introducing newly discovered stabiliz-
ing mutations into the more stable wild-type enzyme will yield mutant
enzymes with extremely high stability.
This approach has been reported for evolving α-amylase to be
extremely stable at high temperatures.65 This is significant because
α-amylase is a key enzyme in the breakdown of starch, an important
industrial process that is performed at high temperatures (e.g., 90C).
The investigators initially introduced a pair of destabilizing mutations
into the wild-type enzyme and then mutagenized the destabilized var-
iant to identify compensatory mutations that restored stability. They
identified a single mutation (A209V) that largely restored stability and,
by introducing this and related mutations66 into the wild-type
enzyme, the resulting α-amylase variant displayed a 10-fold increase
in its half-life at 90C.65 These and related studies67-69 demonstrate
the power of functional screens to identify rare mutations that result
in extremely high enzyme stability in addition to high activity.
It is also important to consider that the utility of enzymes is not
only linked to their folding stability, but also to their solubility. One
particularly compelling study70 evaluated the impact of nearly every
single mutation on enzyme expression properties—namely enzyme
expression on the surface of yeast cells and enzyme secretion via a
bacterial folding pathway specific for soluble and folded proteins—
that serve as surrogates for protein solubility.71-75 The investigators
screened mutant libraries of a β-lactamase enzyme to identify muta-
tions that promote high expression levels and high expected solubil-
ities.70 Deep sequencing of the enzyme libraries before and after
selection enabled the evaluation of the impact of nearly every muta-
tion on solubility-like properties. By comparing these vast data sets
with previous data sets that quantify the impact of nearly every single
mutation on enzyme fitness (which is correlated with activity),76 they
found that a significant fraction (~40%) of mutations that increase sol-
ubility are detrimental to activity. This striking observation could be
explained in part by the proximity of the solubilizing mutations to the
enzyme active site (mutations close to the active site are more likely
to be detrimental), contact number (mutations at sites with more con-
tacts are more likely to be detrimental), and evolutionary conservation
(mutations at more conserved sites are more likely to be detrimen-
tal).70 Moreover, they also found that mutations beneficial for both
activity and solubility are extremely rare (~0.05–0.15%), which
appears to explain previous observations of trade-offs between
these and related properties such as stability.22,31 This and other
deep sequencing studies77,78 are enabling unprecedented analysis of
trade-offs between enzyme activity, stability and solubility, which is
improving the systematic and reliable generation of enzymes with
optimized properties.
2.3 | Directed evolution of antibody affinity and
stability
The active sites of antibodies, like enzymes, are commonly engineered
to increase their function, and trade-offs between activity and stabil-
ity are also commonplace for antibodies.79-81 In some ways, directed
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evolution of antibodies is simpler than for enzymes because it is easier
to screen for antibody function (binding to target antigens) than it is
to screen for enzyme activity. This is largely because the catalytic
product does not remain stably bound to the enzyme. This significant
difference means that it is only necessary to maintain the linkage
between protein function and DNA sequence for antibody screens,
which eliminates the need for spatial compartmentalization of each
protein variant. The linkage between antibody function and DNA
sequence can be readily accomplished in the laboratory using
methods such as phage, bacterial, and yeast surface display.82-84 This
results in the ability to screen large antibody libraries (106–1010) that
are only limited by DNA transformation efficiency of the host cells.
However, in other ways, it is more challenging to evolve antibody
function (relative to enzyme function) and stability using directed evo-
lution methods. First, identification of antibodies that bind to the
desired target antigen is often complicated by co-selection of anti-
bodies with nonspecific binding activity (e.g., off-target binding). Sec-
ond, it is challenging to screen for both antibody activity and stability
at the same time because most cells (e.g., bacteria), viral particles
(e.g., phage), and antigens used for evolving antibodies are not stable
at high temperature and/or other harsh conditions required for evolv-
ing protein stability. These and other challenges have motivated
researchers to develop innovative approaches for selecting and engi-
neering antibody variants to minimize trade-offs between antibody
activity and stability.
One example of activity/stability trade-offs for antibodies has been
reported for single-domain antibodies specific for the Alzheimer's Aβ
peptide.79,80 The investigators generated a mutant library (>106 vari-
ants) based on a stable, human VH domain and screened for mutants
with increased affinity for the Aβ peptide using yeast surface display
and fluorescence-activated cell sorting (FACS).79 The best variant iso-
lated in the first round of mutation and selection was further
mutagenized and screened for additional increases in affinity. This pro-
cess of mutation and selection was performed four times. Evaluation of
the best clone identified at the end of each round revealed several nota-
ble findings. First, the stabilities of the antibody domains were progres-
sively reduced as the number of mutations increased, and the highly
evolved variants were greatly destabilized and unfolded when produced
as soluble antibody domains. Second, significant reductions in antibody
stability were observed even after the first round of mutagenesis, as the
apparent melting temperature was reduced from 75C for wild-type to
57C for the best variant isolated after the first round. Third, there was
a strong pressure for selection of destabilizing mutations even when
mutations were targeted to the complementarity-determining regions
(CDRs) to avoid non-CDR sites that were known to be important for
stability. For example, antibody domains are typically stabilized by one
highly conserved, intramolecular disulfide bond, and mutations that
eliminate this covalent bond are expected to be highly destabilizing. Sur-
prisingly, even in cases in which the investigators targeted mutations to
the CDRs in order to avoid mutations that disrupt the stabilizing disul-
fide bond, they still obtained variants with cysteine knockout mutations
due to low frequency mutations (introduced due to PCR errors) that
were strongly favored for antigen binding.
To overcome this problem, the investigators sought to repeat the
screening process by co-selecting for both antibody affinity and stabil-
ity at the same time to minimize trade-offs between these two prop-
erties.79 While a variety of methods for evolving affinity and stability
had been reported, there were no previous methods for simulta-
neously selecting for both antibody affinity and stability during
directed evolution studies. Given that it is not possible to perform
antibody selections directly at high temperature due to antigen insta-
bility and poor yeast viability, the investigators evaluated the use of
conformational probes that are specific for stably folded antibody
domains and which could be monitored during FACS to identify anti-
body variants with both high affinity and stability. Notably, the anti-
body domains—which belong to a particular human antibody subclass
(VH3)—are recognized by Protein A via a conformational epitope on
their frameworks.85,86 Although the Protein A binding site is close to
the antigen binding site, the investigators reasoned that both antigen
and Protein A binding could be evaluated at the same time without
interfering with each other.79 Thus, the investigators repeated four
rounds of directed evolution by selecting for both antigen binding and
stability (as judged by Protein A binding), and identified progressively
evolved variants with significant increases in affinity while maintaining
high stability. The variants, which are highlighted in Figure 3, had
increasing numbers of mutations after each round of evolution, includ-
ing 4 mutations after round 1 (P1 variant), 7 after round 2 (P2 variant),
9 after round 3 (P3 variant), and 12 after round 4 (P4 variant).
To understand how the evolved antibody domains minimized
trade-offs between affinity and stability, the investigators performed
reversion mutational analysis to evaluate how each mutation contrib-
uted to both properties (Figure 3b,c).80 Mutations that improve anti-
body affinity or stability are expected to result in reductions in either
property when reverted to wild-type. The directed evolution process
resulted in selection of several mutations that improved affinity
(as evidenced by reduced equilibrium association constants when
reverted to wild-type), such as R62, N72, and R50 (Figure 3b), that
were detrimental to stability (as evidenced by increased melting tem-
peratures when reverted to wild-type; Figure 3c). Such destabilizing
mutations are expected to compromise stability significantly and pre-
vent evolution of stable and high-affinity antibody domains, as the
investigators had observed when performing selections for antibody
affinity without selecting for stability.79 However, the mutational
analysis revealed that two key stabilizing mutations were co-selected,
namely K45 and K98, and these mutations appear to compensate for
the destabilizing effects of several affinity-enhancing mutations.80
These results demonstrate that affinity-enhancing mutations can be
destabilizing, and minimizing trade-offs between antibody affinity and
stability requires selection of compensatory mutations to maintain
thermodynamic stability.
It is also notable that these observations related to affinity/stability
trade-offs are not specific to antibodies but have also been observed for
other affinity (nonimmunoglobin) proteins that have been engineered
using directed evolution methods. For example, a nonimmunoglobin pro-
tein scaffold (DARPin) was subjected to multiple rounds of mutation and
selection for high-affinity binding to a cancer-associated antigen
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(Her2).87 The investigators screened their DARPin libraries using phage
display, which requires antigen immobilization and selection for only one
property at a time (e.g., affinity) and generally does not permit simulta-
neous co-selection for both affinity and stability. This appears to explain
the fact that the progressively evolved variants with increased affinity
resulted in significant reductions in stability. Interestingly, the most highly
evolved variant with high affinity (KD of 0.4 nM) had a much lower stabil-
ity (melting temperature of 57C) relative to wild-type (melting tempera-
ture of 86C). Mutational analysis revealed that the highest affinity
DARPin had accumulated several affinity-enhancing mutations that
were strongly destabilizing and, despite its modest stability, also
accumulated multiple mutations that primarily contributed to
maintaining thermodynamic stability. This and other findings88-90
highlight that directed evolution of antibodies and related affinity
proteins commonly involves activity/stability trade-offs, and selec-
tion of compensatory mutations that maintain thermodynamic stabil-
ity is key to the success of these efforts.
3 | DESIGN METHODS FOR IMPROVING
DIRECTED EVOLUTION OF PROTEIN
ACTIVITY AND STABILITY
Although directed evolution methods have been modified with great
success for the identification of stabilized enzymes and antibodies,
rational design methods hold significant potential to improve the like-
lihood of success for directed evolution experiments. Indeed, a signifi-
cant fraction (~30–50%)91-93 of individual mutations in proteins are
destabilizing, and many gain-of-function mutations have destabilizing
effects on proteins.17,22,27,29,31 A common paradigm of protein library
design methods is to identify “consensus” (ancestral) protein sequences
or stable structural elements that can be sampled during mutagenesis.
In this section, we highlight examples of such design methodologies
and describe instances where these approaches have been successful
for engineering highly active proteins while minimizing activity/stability
trade-offs.
3.1 | Computational methods for identifying activity-
enhancing and stabilizing mutations in enzymes
Consensus-based evolutionary strategies rely on sequence-alignment
of homologous proteins in order to identify residues where the
sequence of the protein of interest has deviated from the ancestral
protein sequence. The consensus design paradigm reasons that com-
mon, naturally occurring residues at a given position in related pro-
teins are more likely to be active and/or stabilizing than a random
mutation because they are frequently found in functional homologs
and are likely present in the ancestral protein. For example, sampling a
contiguous stretch of residues from homologs within flexible regions
of L-arginase, an enzyme with applications in cancer treatment,94 was
recently shown to greatly stabilize and increase enzyme activity.95
F IGURE 3 Antibody directed evolution reveals trade-offs between
affinity and stability. (a) Structural model of an evolved human antibody
(VH) domain, which is referred to as P4. This antibody domain was
identified following four rounds of mutagenesis and co-selection for
affinity (binding to the Alzheimer's Aβ42 peptide) and stability [binding
to a conformational probe (Protein A) that is linked to stability]. (b, c)
Reversion mutational analysis reveals how each mutation selected in
rounds 1–4 of mutagenesis and selection contribute to antibody
(b) affinity and (c) stability. Antibody domain P1 contains
four mutations, P2 contains seven mutations (including the same ones
as P1), P3 contains nine mutations (including the same ones as P1 and
P2) and P4 contains 12 mutations (including the same ones as P1, P2,
and P3). Each mutation was reverted to wild-type, and its impact on
affinity and stability was evaluated. Mutations that increase affinity or
stability are expected to reduce the corresponding property when
reverted to wild-type, and vice versa for mutations that reduce affinity
or stability. In (b), the equilibrium association constant (KA) is reported,
and increased values of KA reflect increased affinity. In (c), the apparent
melting temperature (Tm*) is reported, and increased values of Tm*
reflect increased stability. Statistical significance [p-values < .05 (*) or
.01 (**)] was judged by a two-tailed Student's t test. The data were
obtained from a previous publication,80 and the figure was adapted
from figures in the same previous publication [Color figure can be
viewed at wileyonlinelibrary.com]
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This interesting study—which demonstrates that both activity and sta-
bility can be simultaneously increased if mutations are judiciously
selected—involved optimizing L-arginase through exchanging homolo-
gous sequences in a flexible loop adjacent to the enzyme active site.
This resulted in a doubling of the specific activity of the enzyme, and
the authors observed that enzyme activity appeared inversely related
to flexibility of this loop. Additional improvements in activity (>three-
fold) and half-life at 65C (>sevenfold) were achieved via additional
mutagenesis within the exchanged loop. These findings demonstrate
the power of using limited sequence diversity informed by related,
functional proteins during directed evolution.
Another important example of rational design methods informed
by protein structure is related to the B-Factor Iterative Test (B-FIT),
which identifies flexible sites in a protein crystal structure based on B-
Factors (a measure of the flexibility of a protein at a given residue). It
is expected that these flexible sites can be rigidified to increase pro-
tein stability,96 although notable exceptions have been reported.97,98
Indeed, the stability (half-inactivation temperature) of an enzyme
(lipase) was improved by >40C through iterative saturation mutagen-
esis at residues identified based on B-Factors,96 and subsequent char-
acterization of the enzyme mutants also revealed much higher
tolerance to three organic solvents (acetonitrile, DMSO, and DMF).99
The broader utility of using B-Factors to inform mutagenic regions
during stability engineering has been demonstrated through increasing
the melting temperature of an esterase by 9C with little change to its
activity.100
The importance of rationally designing enzyme libraries with
amino acid diversity in specific regions has also been recently demon-
strated in a variety of examples that involve optimization of substrate
access tunnels of enzyme active sites to improve activity and stabil-
ity.101-109 Several computational tools have been generated for identi-
fying and engineering substrate access tunnels for diverse applications
in enzyme engineering, including altering substrate selectivity (see ref-
erences within a recent review110). A notable example of improving the
stability of enzymes through access tunnel engineering involved
increasing the organic solvent tolerance of a haloalkane dehalogenase
(DhaA).101 High concentrations of DMSO reduce the activity of the
enzyme by approximately an order of magnitude, but one stabilized
variant identified after mutagenesis and selection contained a mutation
within the access tunnel that was entirely responsible for its improved
tolerance to the organic solvent. The mechanism of structural stabiliza-
tion in DMSO appears to be due to improved packing of the hydropho-
bic core, which prevents DMSO access to the folded protein core.101
Moreover, the apparent melting temperature of the enzyme mutant
was improved by 19C following saturation mutagenesis at another
position within its access tunnel. Interestingly, to demonstrate the gen-
erality of stabilization via access tunnel engineering, the authors also
used the FoldX111 computational algorithm to assess the stability
changes for all possible point mutations in a panel of 26 different
enzymes and found that mutations predicted to be highly stabilizing
were preferentially located within the access tunnels.101 Access tunnel
engineering has now also been used for improving the stability of a
lipase in methanol,103 demonstrating the utility of this approach.
Although de novo computational protein design is still in its
infancy, the field holds promise for the generation of enzymes catalyz-
ing novel chemical transformations. Many successfully designed
enzymes are minimally active on the desired substrate, but low levels
of catalytic activity can be a valuable starting point for significant
gains of function obtained via directed evolution.19,20,112 Until
recently, no natural enzymes had been identified that efficiently cata-
lyze the Kemp eliminase reaction, which is an important high-energy
barrier model reaction involving proton transfer from carbon. However,
several Kemp eliminases (i.e., enzymes that catalyze this reaction) with
low levels of activity have been computationally designed.113 While the
activities of two of the designed enzymes could be subsequently
improved (~200- to 400-fold) via directed evolution,114,115 the
engineered enzymes failed to meet the design goals. Furthermore, the
most active computationally designed Kemp eliminase (KE59) was not
amenable to evolutionary optimization due to its low stability. By sam-
pling consensus mutations that were predicted to be stabilizing, the cat-
alytic activity of the enzyme (KE59) was improved ~2,000-fold via
directed evolution.116
Additional computational tools have been created that are
informed by consensus-based sequence information. For instance, the
PRotein One Stop Shop (PROSS) algorithm was developed for stabili-
zation and high-level expression of proteins with solved molecular
structures.117 PROSS analyzes homologous protein sequences and
locates mutations that are most frequently observed at each position
within the protein family. Importantly, the algorithm can be instructed
to avoid active-site residues or other positions known to be important
for function. Using the molecular structure of the protein, Rosetta
simulations then identify individual mutations that are predicted to
stabilize the protein structure. Next, protein mutants containing com-
binations of these mutations are then designed using Rosetta combi-
natorial sequence optimization to identify variants with improved
native-state energy. Such an approach was employed during directed
evolution to convert bacterial phosphotriesterases into efficient nerve
agent bioscavengers with high activity against both VX and Russian
VX.118 Prior efforts to engineer these phosphotriesterases had
reached an optimization plateau short of the catalytic design goals.
The PROSS design tool was used to guide library design for stabiliza-
tion of the phosphotriesterases, and this enabled additional produc-
tive rounds of directed evolution and incorporation of previously
identified beneficial mutations that were not well tolerated when
introduced into the less stable phosphotriesterases.118 PROSS has
also been used to stabilize the malaria invasion protein PfRH5, a
promising malaria vaccine candidate, without disrupting its immuno-
genicity or ligand binding.119 This stabilized version of the protein
could enhance its utility when deployed in challenging climates that
are common to malaria infections.
Consensus-based protein sequence analysis is also helpful for iden-
tifying stabilizing, global suppressor mutations. However, primary
sequence alignments do not typically consider the disruption of second-
ary and tertiary structures that can arise from mutating sites in proteins
to consensus residues. Therefore, many efforts have been made to cre-
ate novel chimeric proteins, wherein domains from different proteins
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are exchanged or recombined to improve or gain new functions. How-
ever, determining the optimal locations for such recombination events
is challenging. A significant development for addressing this problem—
namely a structure-based algorithm (referred to as SCHEMA)—was
developed in Frances Arnold's laboratory. This approach is based on cal-
culating disruptions of residue-residue contacts upon exchanging one
domain (or schema) of a protein with the corresponding domain from
another homologous protein.120 For example, random chimeric libraries
analyzed in silico (containing 8-domain chimeras assembled from three
related P450 enzymes) revealed that 14 recombination sites were dom-
inant in libraries predicted to contain a high fraction of properly folded
chimeras.121 A diverse library designed to use seven of these 14 cross-
over sites was constructed and used to identify an enzyme variant
whose melting temperature was increased by 7C relative to any of the
parent enzymes. Notably, the SCHEMA-guided design can improve the
fraction of properly folded enzyme variants in libraries by more than
three orders of magnitude compared to traditional enzyme libraries
containing similar amounts of sequence diversity.51
3.2 | Computational methods for identifying affinity-
enhancing and stabilizing mutations in antibodies
Computational antibody engineering is an attractive complementary
method that can be used in conjunction with traditional directed evolu-
tion methods to enable in silico screening of much larger numbers of
mutants than would be possible experimentally. We highlight in this
review selected examples in which computational methods have been
used successfully for optimizing antibody properties, and additional ref-
erences can be found in a more comprehensive review.122 Computa-
tional methods have been primarily used to improve either antibody
activity (affinity and specificity) or stability. Many such approaches rely
on calculating energy differences between a given antibody mutant of
interest relative to wild-type, which are typically performed using soft-
ware programs such as Rosetta,123 CHARMM124 and others.125,126
Several research groups have demonstrated that these computa-
tional approaches can be successfully used for antibody affinity matu-
ration or stabilization.127-139 For example, one study of multiple
F IGURE 4 Combined computational design and directed evolution for optimizing antibody affinity and stability. The evolutionary path of a
single-chain variable fragment (scFv, specific for the MS2 phage protein) to a stabilized, affinity-matured full-length (IgG) antibody is illustrated by
tracking its progression through the affinity/stability landscape. (1) The initial scFv used for CDR grafting was only modestly stable. (2) Grafting
the CDRs of the scFv onto a full-length antibody improved stability, but decreased affinity. (3) Computational optimization of the interface
between the variable (VH and VL) domains resulted in improved stability and affinity. (4) Incorporation of a computationally designed
intramolecular disulfide bond into the variable heavy (VH) domain further increased both stability and affinity. (5) Additional mutations predicted
based on consensus and computational design further increased stability without compromising affinity. (6) Introduction of a designed
intramolecular disulfide bond in the second constant region of the heavy chain (CH2) modestly improved both antibody stability and affinity.
(7) Finally, the CDRs were affinity matured in the context of a suboptimal antibody and then grafted onto the stabilized framework to yield an
optimized antibody with both high stability (melting temperature > 90C) and high affinity (equilibrium dissociation constant of <1 nM). The data
were obtained from a previous publication,142 and the figure was adapted from one in the same previous publication [Color figure can be viewed
at wileyonlinelibrary.com]
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antibodies demonstrated that calculations of electrostatic interactions
gave better predictions of affinity improvements relative to the full
energy function, which includes contributions from nonelectrostatic
interactions.127 Similar results have been reported by several other
groups, where mutations that improved antibody/antigen electrostatic
interactions resulted in dramatic improvements in affinity.128-130 For
improving antibody stability, a relatively simple approach is to graft
the CDRs with desired antigen specificity onto a known stable anti-
body framework that is predicted to be compatible with the
CDRs.133,139 However, unexpected incompatibilities between the
CDRs and the desired framework can alter loop conformations and
thereby reduce affinity.140,141 Another promising method is to use con-
sensus design to incorporate mutations into the destabilized antibody
that are commonly observed in stable antibodies.134 Finally, the introduc-
tion of non-native inter- and intra-domain disulfide bonds into antibody
variable regions has been shown to significantly improve stability,137,138
albeit at the expense of increasing the complexity of the molecule.
Nevertheless, given that affinity-enhancing mutations have an
increased risk of being destabilizing and stabilizing mutations may
compromise affinity (depending on how they influence the active
site), it remains challenging to predict the interplay between affinity-
enhancing and stabilizing mutations. Therefore, it is important to
integrate computational approaches into the directed evolution pro-
cess that are capable of predicting either affinity-enhancing or stabi-
lizing mutations in order to minimize the trade-offs between the two
properties.
A strong example of combining computational design methods
and experimental (directed evolution) methods was reported for opti-
mizing the affinity and stability of an antibody specific for a bacterial
phage protein (Figure 4).142 The investigators first stabilized a single-
chain antibody by grafting the CDRs onto a stable IgG framework.
While the resulting antibody was more stable (Tm increased from
67 to 69C), its affinity was reduced approximately threefold. Never-
theless, the researchers further optimized antibody stability by engi-
neering the interface between the variable regions [variable heavy
(VH) and variable light (VL)] by mutating multiple residues of the stable
framework (identified using previously described methods140) back to
those in the parental antibody. The stabilization of the VH/VL interface
increased the melting temperature by >8C and increased the affinity
back to levels similar to wild-type. The stability was also increased fur-
ther by computationally designing an additional intramolecular disul-
fide bond in the VH domain.
137,138 RosettaDesign123 software
predicted that the disulfide bond would stabilize the antibody, which
was also verified experimentally.142 Interestingly, this additional disul-
fide bond not only increased antibody stability (Tm of 84C), but also
improved its affinity. These and additional stabilization steps, includ-
ing consensus and computational design, resulted in an extremely sta-
ble antibody (Tm of 90.3C) with improved affinity (equilibrium
dissociation constant [KD] of 2.5 nM).
Finally, it was unclear if the highly stable antibody could be further
affinity matured while retaining its extremely high stability (Figure 4).142
Therefore, the investigators performed directed evolution to identify
affinity-enhancing mutations in the CDRs using in vitro somatic
hypermutation and mammalian cell display,142,143 and identified several
CDR mutations that (when combined) led to a >27-fold improvement in
affinity. Notably, the resulting antibody maintained its stability (90.1C
for the affinity-matured variant relative to 90.3C for the parental anti-
body). This and related studies144,145 demonstrate how integrating com-
putational and experimental approaches can enable the optimization of
both antibody affinity and stability while minimizing trade-offs between
these properties.
4 | CONCLUSIONS
The success of directed evolution for generating highly active proteins
requires methods for addressing and minimizing activity/stability
trade-offs. The studies reviewed here—including pioneering studies
from Frances Arnold's lab—demonstrate that activity-enhancing muta-
tions are commonly destabilizing, and compensatory mutations are
required to maintain thermodynamic stability. Given the unimaginably
large chemical diversity that is possible for all combinations of muta-
tions within a single protein, an important future direction will be to
further improve library design methods to focus amino acid diversity
in protein libraries on the small fraction of sequence space that is
likely to yield both highly active and stable proteins. This ambitious
goal—which is starting to be realized70,77,78—will require improve-
ments in the prediction of both activity-enhancing and stabilizing
mutations, and assessment of the complex interplay between these
two properties. Combining such novel library design approaches with
emerging screening methods that enable unprecedented throughput
are expected to lead to successful generation of proteins with levels
and types of activities that have previously been unattainable to pro-
tein engineers. Such advances are critically important for solving many
of the most pressing challenges related to energy, the environment
and human health.
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